Single Dose PG102 in Patients With Active Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00787137
Recruitment Status : Terminated (poor recruitment)
First Posted : November 7, 2008
Results First Posted : October 15, 2010
Last Update Posted : October 26, 2010
Information provided by:
PanGenetics UK Limited

Brief Summary:
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease.

Condition or disease Intervention/treatment Phase
Arthritis, Psoriatic Drug: PG102 Drug: Placebo comparator Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis
Study Start Date : December 2008
Actual Primary Completion Date : April 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PG102 0.3 mg/kg
Lowest dose PG102
Drug: PG102
A single intravenous infusion
Other Name: Anti-CD40 monoclonal antibody

Experimental: PG102 1 mg/kg
Second dose PG102
Drug: PG102
A single intravenous infusion
Other Name: Anti-CD40 monoclonal antibody

Placebo Comparator: Placebo (phosphate-buffered saline)
Drug: Placebo comparator
Phosphate-buffered saline

Primary Outcome Measures :
  1. The Number of Reported Adverse Events [ Time Frame: Three months ]
    This was an exploratory study and all safety endpoints were considered.

  2. The Percentage of Participants With Adverse Events [ Time Frame: Three months ]
  3. The Number of Episodes of Change in Vital Signs [ Time Frame: Three months ]
    Clinically significant episodes of change in blood pressure, heart rate, temperature or respiration rate on the day before dosing and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours and 4, 7, 14, 21, 28, 56 & 84 days after dosing. The investigator evaluated clinical significance primarily by blinded comparison with the respective screening value.

  4. The Number of Episodes of Change in Electrocardiogram [ Time Frame: Three months ]
    Episodes of clinically significant change in 12-lead electrocardiogram predose,1 & 4 hours and 1 & 84 days postdose. The investigator evaluated clinical significance primarily by blinded comparison with the screening electrocardiogram.

  5. The Number of Episodes of Change From Screening in Laboratory Assessments [ Time Frame: Three months ]
    Red cell count, haemoglobin, haematocrit, total and differential white cell counts, platelet count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, reticulocytes; urea, creatinine, urate, bilirubin, sodium, potassium, calcium, phosphate, chloride, bicarbonate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gammaglutamyl transferase, creatine phosphokinase, albumin, protein; urine pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, nitrite, leucocytes, specific gravity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Arthritis that meets Classification of Psoriatic Arthritis (CASPAR) criteria
  • Plaque psoriasis for at least 6 months prior to study enrollment

Exclusion Criteria:

  • Clinically significant psoriasis flare
  • Unstable doses of pain relief medication
  • Treatment with systemic corticosteroids other than prednisone ≤ 10 mg/day or equivalent
  • Treatment with any biologic therapy
  • Treatment with immunosuppressive agents or disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate
  • Treatment with lithium, any anti-malarial, chlorambucil, cyclophosphamide or therapies for psoriasis other than low potency topical corticosteroids on intertriginous and groin areas, tar or salicylate preparations on the scalp, and emollients and moisturisers
  • Family history of multiple thrombotic events or a personal history of any venous or arterial thrombotic event
  • Clinically significant result for anti-cardiolipin, Activated protein C resistance test, Protein C, Free Protein S, Antithrombin III, Factor V Leiden, Prothrombin variant, Homocysteine, Lupus anticoagulant, Prothrombin time, Activated partial thromboplastin time, Fibrinogen, Thrombin time, Factors IX and XI
  • Currently smoking ≥ 10 cigarettes per day or equivalent
  • Active tuberculosis or other infection
  • Current or previous malignancies
  • Clinically significant abnormality on physical examination, laboratory testing, vital signs or 12-lead electrocardiogram

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00787137

Professor Nemanja Damjanov
Belgrade, Serbia
Sponsors and Collaborators
PanGenetics UK Limited
Principal Investigator: Nemanja Damjanov, MD PhD Institute of Rheumatology, Belgrade, Serbia

Responsible Party: John Powell, PanGenetics UK Limited Identifier: NCT00787137     History of Changes
Other Study ID Numbers: PG102-01
2007-001017-42 ( EudraCT Number )
First Posted: November 7, 2008    Key Record Dates
Results First Posted: October 15, 2010
Last Update Posted: October 26, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs